← Back to Search

Monoclonal Antibodies

ZM008 Alone and With Pembrolizumab for Cancer

Phase 1
Research Sponsored by Zumutor Biologics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate renal function: Estimated creatinine clearance (CrCL) ≥30 mL/minute
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) scan
Must not have
Live vaccines reception within 30 days of enrollment
History of pneumonitis/interstitial lung disease
Screening 3 weeks
Treatment Varies
Follow Up assessed at study completion in upto 36 months.
Awards & highlights


This trial is testing a new drug called ZM008 in patients with advanced solid tumors who have already tried standard treatments or cannot tolerate them. The drug will be given alone at first and then in combination

Who is the study for?
This trial is for patients with various advanced solid tumors, like breast, lung, and prostate cancer, who have no standard treatment options left or can't tolerate them. It's not specified who can't join the trial.Check my eligibility
What is being tested?
The study tests ZM008 alone and combined with Pembrolizumab to find safe doses in people whose cancers haven't responded to typical treatments. It's an early-stage (phase 1) dose-finding study.See study design
What are the potential side effects?
Since it's a phase 1 trial of ZM008, specific side effects aren’t listed but may include typical reactions to new cancer drugs such as fatigue, nausea, and immune-related responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My kidneys are functioning well enough (CrCL ≥30 mL/min).
My cancer can be measured on scans.
I am over 18 years old.
My cancer has specific mutations and I've tried all suitable targeted treatments without success or cannot take them due to health reasons.
I am fully active or can carry out light work.
My blood counts meet the required levels for treatment.
My cancer is advanced and cannot be cured with standard treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have not received any live vaccines in the last 30 days.
I have had lung inflammation or scarring before.
I have a serious health condition that is not under control.
I do not have major heart problems.
I stopped previous immunotherapy due to side effects.
I have brain metastasis that is not currently under control.
I am not currently on antibiotics for an infection.
I have another type of cancer that is currently active.
I have an autoimmune disease treated with drugs that affect my immune system.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at study completion in upto 36 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at study completion in upto 36 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Heart Rate
Change in systolic and diastolic BP
Changes in Temperature measurements.
+1 more
Secondary outcome measures
Area Under the Plasma Concentration Versus Time Curve (AUC) of the biological product ZM008
Disease Control Rate
Immune Disease Control Rate
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Dose escalation of ZM008.

Find a Location

Who is running the clinical trial?

Zumutor Biologics Inc.Lead Sponsor
Maloy Ghosh, PhDStudy ChairZumutor Biologics Inc.
Jyotsna FuloriaStudy DirectorFuloria Clinical Research Solutions LLC
~22 spots leftby Dec 2026